Combination and newer therapies for chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 3, 2002, Pages

  Schalm, S W ^a   De Man, R A ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOCOMPETENCE; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; VIRUS CARRIER; VIRUS INACTIVATION;

EID: 0036458876     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s3.24.x     Document Type: Conference Paper

References (22)

1. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon-alpha. Hepatology 1997; 26: 1338-42.
2. Bortolotti F, Jara P, Barbera C et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715-18.
3. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 1996; 334: 1422-7.
4. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.
5. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-8.
6. VanNunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg Seroconversion following Antiviral Therapy for Chronic Hepatitis B: Relation to Type of Therapy and Pre-treatment Serum HBV DNA and ALT. submitted.
7. Realdi G, Alberti A, Rugge Met al. Seroconversion from HBe antigen to antiHBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79: 195-9.
8. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med. 1981; 94: 744-8.
9. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B 2000: Summary of a workshop. Gastroenterology 2001; 120: 1828-53.
10. De Franchis R, Meucci G, Vecchi M et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann. Intern. Med. 1993; 118: 191-4.
11. Cooksley G et al. A phase II open label study evaluating the safety and efficacy of pegylated interferon-alpha 2a in interferon-naïve patients with chronic hepatitis B. AASLD. Hepatology 2001; 34: 349A.
12. Marcellin P, Chang TT, Lim SG et al. A double blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 Week results. AASLD. Hepatology 2001; 34: 340A.
13. Lai CL et al. Entecavir vs lamivudine in chronic hepatitis B. J. Hepatol. 2001; 34 (Suppl.): 24.
14. Hadziyannis S et al. Entecavir in patients with chronic hepatitis B failing lamivudine. AASLD. Hepatology 2001; 34: 340A.
15. Johnson MA, Jenkins JM, Bye C. A study of the pharmacokinetic interaction between lamivudine and alpha interferon. Eur. J. Clin. Pharmacol. 2000; 56: 289-92.
16. Mutimer D, Naoumov N, Honkoop P et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon resistant chronic hepatitis B infection: Results of a pilot study. J. Hepatol. 1998; 28: 923-9.
17. Schiff ER, Karayalcin S, Grimm IS et al. Lamivudine and Lamivudine/Interferon Combination Therapy in Patients with Hepatitis B who previously failed Interferon. An International Controlled Trial. submitted.
18. Barbaro G, Zechini F, Pellicelli AM et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J. Hepatol. 2001; 35: 406-11.
19. VanNunen A, Hansen BE, Mutimer D et al. Lamivudine and Interferon Combination Therapy in Chronic Hepatitis B. A Study of Viral Kinetics. submitted..
20. Perillo R, Schiff E, Hann HWL et al. Addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B with YMDD variant HBV. AASLD. Hepatology 2001; 34: 349A.
21. Schiff ER, Neuhaus P, Tillmann H et al. Adefovir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation. AASLD. Hepatology 2001; 34: 349A.
22. Perrillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581-6.